Off-Target Effects with Matt Gline

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's

Episode 6: BridgeBio Founder & CEO Neil Kumar discusses the hub and spoke biotech model and trying to build a sustainable business for the long-term

He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares

Episode 5: John Maraganore has been a champion of innovation throughout his career. He discusses the road to success at Alnylam, today's environment, and keeping the U.S. on top

Reflecting on the decades-long journey at Alnylam, John Maraganore describes making it through lean times, and how far oligos and RNAi have come today. Matt asks him abou

Episode 4: Matt speaks with Philip Ross, one of the most experienced and successful bankers in healthcare, about the M&A landscape and his decision to join Jefferies last year

Philip Ross talks about the outlook for M&A in our industry, and describes the pharma revenue growth demands that will be driving it. He discusses what qualities make tar

Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries

Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his philosophy of writing for investo

Episode 2: Matt speaks with Avoro Capital's Behzad Aghazadeh about the hot button issues that have been striking the biotech sector

One of the largest and most successful biotech investors, Dr. Aghazadeh is asked about key current events like turnover at FDA, tariffs, China, and whether he thinks biot

Episode 1: From SF Healthcare Week, Matt interviews Brad Loncar about M&A and China's potential impact on it

For the first episode of the new video podcast, Matt turns the tables on Brad Loncar and interviews him about his experiences and knowledge of investing in China biotech